Table 1.
Characteristic | No. (%) |
---|---|
Median patient age at second-line treatment, range , y | 48 (1-73) |
Patient gender | |
Male | 175 (56) |
Female | 137 (44) |
Donor-patient gender combination | |
Female to male | 89 (29) |
Other | 223 (71) |
Diagnosis | |
Myeloid malignancy | 208 (67) |
Lymphoid malignancy | 85 (27) |
Other/nonmalignant | 19 (6) |
Disease risk at transplantation* | |
Low | 131 (42) |
High | 181 (58) |
Conditioning regimen | |
High intensity without TBI | 135 (43) |
High intensity with TBI | 75 (24) |
Reduced intensity | 102 (33) |
Graft source | |
Bone marrow | 35 (11) |
Mobilized blood cells | 265 (85) |
Umbilical cord blood | 12 (4) |
Donor and HLA type | |
HLA-matched related | 130 (42) |
HLA-matched unrelated | 118 (38) |
HLA antigen or allele-mismatched related | 9 (3) |
HLA antigen or allele-mismatched unrelated | 55 (18) |
Median time from transplantation to initial systemic treatment, months (range) | 5.4 (2.2-29) |
Initial systemic treatment | |
Prednisone + CNI | 201 (64) |
Prednisone + CNI + mycophenolate mofetil | 50 (16) |
Prednisone alone | 37 (12) |
Prednisone + others | 24 (8) |
TBI, total body irradiation; HLA, human leukocyte antigen; CNI, calcineurin inhibitor.
The low-risk category included chronic myeloid leukemia in chronic phase, acute leukemia in first remission, myelodysplastic syndrome without excess blasts, and nonmalignant diseases. The high-risk category included all other diseases and stages.